US International Trade Commission Judge Finds Fujifilm Infringes on Hologic Patents
MARLBOROUGH, Mass., July 30, 2018 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that an Administrative Law Judge of the U.S. International Trade Commission (ITC) has issued a favorable initial ruling in the investigation of the patent infringement complaint filed by Hologic, Inc. against Fujifilm.
The asserted patents pertain to x-ray mammography with tomosynthesis and other related mammography technologies found in Hologic's market-leading Selenia® Dimensions® and 3Dimensions(TM) systems, which are manufactured in the United States. These technologies contribute to Hologic's innovative 2D and 3D(TM) combination exam which is FDA approved as superior to 2D mammography alone, has been found to detect 20-65% more invasive breast cancers*(,1), and reduces callbacks by up to 40%*(,2,3).
As part of the initial ruling, the Judge ruled that Fujifilm infringed all of the patents brought to trial and rejected Fujifilm's defenses against these patents. As a result of this ruling, the Judge recommended an exclusion order that prevents the importation of infringing Fujifilm products into the United States, as well as a cease-and-desist order preventing the further sale and marketing of infringing Fujifilm products in the United States. A final ruling by the ITC is scheduled to issue by November 26, 2018.
"We are pleased that the Administrative Law Judge has upheld the integrity of our intellectual property against Fujifilm," said Pete Valenti, President of Breast and Skeletal Health at Hologic. "We are confident that the Commission will uphold the decision to issue both an exclusion order and a cease-and-desist order covering Fujifilm's infringing products. As the world leader and innovator in mammography, we will continue to vigorously protect our intellectual property, which drives innovation for our customers and patients."
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, 3D, 3Dimensions, Dimensions, Selenia, The Science of Sure, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
Media Contact:
Jane Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael Watts
858.410.8588
Michael.watts@hologic.com
*Compared to 2D mammography alone
(1) Friedwald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25; 311(24):2499-2507
(2) Bernard D, Macaskill P, Pellegrini M, et. Al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STOMR-2); a population based prospective study. Lancet Oncol. 2016 Aug; 17(8):1105-13
(3) Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia Dimensions on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D(TM) mammograms acquired with the Hologic 3D Mammography(TM) System versus women receiving 2D FFDM mammograms only.
View original content:http://www.prnewswire.com/news-releases/us-international-trade-commission-judge-finds-fujifilm-infringes-on-hologic-patents-300688210.html
SOURCE Hologic, Inc.
